HAE Stock — Haemonetics Corp.

Haemonetics Corp. (HAE)

Updated October 16, 2026.

HAE is a Stock. Total return is 1892.1% over the past 35.4 years.

Haemonetics Corporation is a Boston-based medical technology company that develops and sells hospital equipment and solutions across three main segments: plasma collection systems and donor management software; surgical hemostasis and monitoring devices; and blood management and transfusion products. The company's portfolio includes automated plasma collection equipment, guidewires for cardiac procedures, viscoelastic analyzers for assessing blood clotting, autologous blood recovery systems, and vascular closure devices, which it distributes through a direct sales force and independent distributors. Haemonetics does not currently have an established distribution schedule.

HAE performance

Price and return data through 2026-10-16.

Total return is 1892.1% over the past 35.4 years. Over the past year its total return — price change plus distributions reinvested — is 137.7%. Its deepest 1-year drawdown was 40.1%.

HAE key facts

Asset type

Stock

Asset class

Equity

Inception date

05/10/1991

Distribution frequency

None

Last close

$118.28 (as of 2026-10-16)

Market cap

$5,381,391,192

Average volume

471311.0

Beta

0.608

Payout ratio

0.0%

P/E ratio

57.14

Forward P/E

20.3252

EPS

$2.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HAE risks and drawbacks

The deepest 1-year drawdown on record here is 40.1%.

Who may consider HAE — and who may not

It is a weaker fit for investors who need monthly cash flow (HAE does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on HAE

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions